CPA
SGMO

Capital Performance Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Capital Performance Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200
Closed -$173 – 2244
2024
Q3 		$173 Buy
+200
New +$147 ﹤0.01% 2589

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Capital Performance Advisors's SGMO Position: Q4 2024 in Review

Capital Performance Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2024, closing a stake of 200 shares — an estimated $173 sold.

Capital Performance Advisors first reported a position in SGMO in Q3 2024 and held it in 1 quarter. The position peaked at $173 in Q3 2024. 128 funds tracked by Wall St. Rank hold SGMO as of Q4 2024.

  • Capital Performance Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 200 SANGAMO THERAPEUTICS INC shares in Q4 2024, an estimated $173.
  • Capital Performance Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's SANGAMO THERAPEUTICS INC position peaked at $173 in Q3 2024.
  • 128 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.